← Eichor
Study identifier: NCT05887284 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Investigation of the Clinical Efficacy of Low-dose Ionizing Radiation in the Treatment of Osteoarthritis

Condition: Arthrosis · Osteoarthritis  ·  Sponsor: University of Erlangen-Nürnberg Medical School

PhaseNA
Planned participants132
Who can joinAll sexes, 39 Years to no upper limit
Healthy volunteersNo

About this study

IMMO-LDRT02 is a prospective, placebo-controlled, double-blind, randomized trial to investigate the clinical efficacy of low dose radiation therapy (LDRT) in the treatment of arthrosis. Newly diagnosed or already existing arthroses of the fingers, wrists, shoulders, knees, ankles and feet will be enclosed. Finally, the evidence of clinical benefit from LDRT (6 x 0.5 Gy) will be compared to the placebo group (6 x 0 Gy), by determination via a visual analog scale and identification of immunological changes.

This description comes directly from the study's public registry record.

Talk to the study team

Benjamin Frey, PD Dr.-Ing.  ·  +49 9131 85  ·  benjamin.frey@uk-erlangen.de

Anna-Jasmina Donaubauer, Dr.  ·  +49 9131 85  ·  anna-jasmina.donaubauer@uk-erlangen.de

Always discuss trial participation with your own doctor first.

Locations (1)

Department of Radiation Oncology, Universitätsklinikum ErlangenErlangen, Bavaria, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05887284